English version of this page

Publikasjoner

Her finner du gruppens utvalgte publikasjoner

Lam CSP, Docherty KF, Ho JE, McMurray JJV, Myhre PL, Omland T. Recent successes in heart failure treatment. Nat Med. 2023 Oct;29(10):2424-2437. doi: 10.1038/s41591-023-02567-2. Epub 2023 Oct 9. PMID: 37814060. Recent successes in heart failure treatment - PubMed (nih.gov)
Sigurdardottir FD, Bertisch SM, Reid ML, deFilippi CR, Lima JAC, Redline S, Omland T. Association between insomnia phenotypes and subclinical myocardial injury: the Multi-Ethnic Study of Atherosclerosis. Sleep. 2023 Apr 12;46(4):zsac318. doi: 10.1093/sleep/zsac318. PMID: 36579654; PMCID: PMC10091090. Association between insomnia phenotypes and subclinical myocardial injury: the Multi-Ethnic Study of Atherosclerosis - PubMed (nih.gov)
Lyngbakken MN, Kimenai DM, Hveem K, Dalen H, Røsjø H, Omland T. Patterns of Cardiac Troponin I Concentrations as Risk Predictors of Cardiovascular Disease and Death: The Trøndelag Health Study. Am J Med. 2023 Sep;136(9):902-909.e4. doi: 10.1016/j.amjmed.2023.05.009. Epub 2023 May 23. PMID: 37225115. Patterns of Cardiac Troponin I Concentrations as Risk Predictors of Cardiovascular Disease and Death: The Trøndelag Health Study - PubMed (nih.gov)
Omland T, Heck SL, Gulati G. The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022 Mar 15;4(1):19-37. doi: 10.1016/j.jaccao.2022.01.101. PMID: 35492815; PMCID: PMC9040117. Times cited: 35. Most read/downloaded JACC CardioOncol article in 2022. The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review - PubMed (nih.gov)
Skranes JB, Lyngbakken MN, Hveem K, Røsjø H, Omland T. Tobacco Consumption and High-Sensitivity Cardiac Troponin I in the General Population: The HUNT Study. J Am Heart Assoc. 2022 Jan 18;11(2):e021776. doi: 10.1161/JAHA.121.021776. Epub 2022 Jan 8. PMID: 35001649; PMCID: PMC9238518. Tobacco Consumption and High-Sensitivity Cardiac Troponin I in the General Population: The HUNT Study - PubMed (nih.gov)
Moksnes MR, Røsjø H, Richmond A, Lyngbakken MN, Graham SE, Hansen AF, Wolford BN, Gagliano Taliun SA, LeFaive J, Rasheed H, Thomas LF, Zhou W, Aung N, Surakka I, Douville NJ, Campbell A, Porteous DJ, Petersen SE, Munroe PB, Welsh P, Sattar N, Smith GD, Fritsche LG, Nielsen JB, Åsvold BO, Hveem K, Hayward C, Willer CJ, Brumpton BM, Omland T. Genome-wide association study of cardiac troponin I in the general population. Hum Mol Genet. 2021 Oct 13;30(21):2027-2039. doi: 10.1093/hmg/ddab124. PMID: 33961016; PMCID: PMC8522636. Genome-wide association study of cardiac troponin I in the general population - PubMed (nih.gov)
Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16. PMID: 33993702; PMCID: PMC8212877. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol - PubMed (nih.gov)
Lyngbakken MN, Kvisvik B, Aagaard EN, Berge T, Pervez MO, Brynildsen J, Tveit A, Steine K, Røsjø H, Omland T. B-Type Natriuretic Peptide Is Associated with Indices of Left Ventricular Dysfunction in Healthy Subjects from the General Population: The Akershus Cardiac Examination 1950 Study. Clin Chem. 2021 Jan 8;67(1):204-215. doi: 10.1093/clinchem/hvaa257. PMID: 33279958. B-Type Natriuretic Peptide Is Associated with Indices of Left Ventricular Dysfunction in Healthy Subjects from the General Population: The Akershus Cardiac Examination 1950 Study - PubMed (nih.gov)
Myhre PL, Prebensen C, Jonassen CM, Berdal JE, Omland T. SARS-CoV-2 Viremia is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients Hospitalized for COVID-19. J Am Heart Assoc. 2021 May 4;10(9):e019756. doi: 10.1161/JAHA.120.019756. Epub 2021 Feb 18. PMID: 33596668; PMCID: PMC8200723. SARS-CoV-2 Viremia is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients Hospitalized for COVID-19 - PubMed (nih.gov)
Myhre PL, Prebensen C, Strand H, Røysland R, Jonassen CM, Rangberg A, Sørensen V, Søvik S, Røsjø H, Svensson M, Berdal JE, Omland T. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19. Circulation. 2020 Dec;142(22):2128-2137. doi: 10.1161/CIRCULATIONAHA.120.050360. Epub 2020 Oct 15. PMID: 33058695; PMCID: PMC7688084. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19 - PubMed (nih.gov)
Omland T, Prebensen C, Røysland R, Søvik S, Sørensen V, Røsjø H, Svensson M, Berdal JE, Myhre PL. Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19. Circulation. 2020 Nov 10;142(19):1878-1880. doi: 10.1161/CIRCULATIONAHA.120.050089. Epub 2020 Sep 10. PMID: 32910681; PMCID: PMC7643784. Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19 - PubMed (nih.gov)
Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rueegg CS, Rangberg A, Jonassen CM, Omland T, Røsjø H, Dalgard O. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020 Oct 20;11(1):5284. doi: 10.1038/s41467-020-19056-6. PMID: 33082342; PMCID: PMC7576792. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics - PubMed (nih.gov)
Omland T. Cardio-Protective Therapy in Cardio-Oncology: Quo Vadis? Circulation. 2021 Aug 31;144(9):667-669. doi: 10.1161/CIRCULATIONAHA.121.055541. Epub 2021 Aug 30. PMID: 34460325. Cardio-Protective Therapy in Cardio-Oncology: Quo Vadis? - PubMed (nih.gov)
Skranes JB, Claggett BL, Myhre PL, Lyngbakken MN, Solomon SD, Sabatine MS, Pfeffer MA, Omland T. Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial. Circulation. 2019 Dec 10;140(24):2044-2046. doi: 10.1161/CIRCULATIONAHA.119.041991. Epub 2019 Dec 9. PMID: 31815543. Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial - PubMed (nih.gov)
Lyngbakken MN, Røsjø H, Holmen OL, Dalen H, Hveem K, Omland T. Temporal Changes in Cardiac Troponin I Are Associated with Risk of Cardiovascular Events in the General Population: The Nord-Trøndelag Health Study. Clin Chem. 2019 Jul;65(7):871-881. doi: 10.1373/clinchem.2018.301069. Epub 2019 Apr 17. PMID: 30996050. Temporal Changes in Cardiac Troponin I Are Associated with Risk of Cardiovascular Events in the General Population: The Nord-Trøndelag Health Study - PubMed (nih.gov)
Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 Jun 1;37(21):1671-80. doi: 10.1093/eurheartj/ehw022. Epub 2016 Feb 21. PMID: 26903532; PMCID: PMC4887703. Times cited: 643 Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol - PubMed (nih.gov)
Ottesen AH, Louch WE, Carlson CR, Landsverk OJB, Kurola J, Johansen RF, Moe MK, Aronsen JM, Høiseth AD, Jarstadmarken H, Nygård S, Bjørås M, Sjaastad I, Pettilä V, Stridsberg M, Omland T, Christensen G, Røsjø H. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol. 2015 Feb 3;65(4):339-351. doi: 10.1016/j.jacc.2014.10.065. PMID: 25634832. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling - PubMed (nih.gov)
Omland T, de Lemos JA, Sabatine MS, et al; Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009 Dec 24;361(26):2538-47. doi: 10.1056/NEJMoa0805299. Epub 2009 Nov 25. PMID: 19940289; PMCID: PMC2997684. A sensitive cardiac troponin T assay in stable coronary artery disease - PubMed (nih.gov)

Publisert 12. feb. 2024 12:55 - Sist endret 12. feb. 2024 13:04